{"id":5104,"date":"2025-05-29T16:51:04","date_gmt":"2025-05-29T16:51:04","guid":{"rendered":"https:\/\/www.podermexico.mx\/?p=5104"},"modified":"2025-05-29T16:51:06","modified_gmt":"2025-05-29T16:51:06","slug":"eli-lilly-consolida-la-adquisicion-de-siteone-therapeutics","status":"publish","type":"post","link":"https:\/\/www.podermexico.mx\/?p=5104","title":{"rendered":"Eli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">La farmac\u00e9utica <strong>Eli Lilly<\/strong> ha anunciado la adquisici\u00f3n de <strong>SiteOne Therapeutics<\/strong>, una biotecnol\u00f3gica especializada en el desarrollo de <strong>medicamentos no opioides<\/strong> para tratar el <strong>dolor cr\u00f3nico<\/strong> y otros trastornos relacionados con la <strong>hiperexcitabilidad neuronal<\/strong>. Con esta operaci\u00f3n, Lilly liderar\u00e1 la fase <strong>2 de ensayos cl\u00ednicos<\/strong> del compuesto <strong>STC-004<\/strong>, con el objetivo de su futura <strong>comercializaci\u00f3n internacional<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La transacci\u00f3n permitir\u00e1 a SiteOne y sus accionistas recibir hasta <strong>1,000 millones de d\u00f3lares<\/strong>, incluyendo un <strong>pago inicial<\/strong> y montos adicionales sujetos al cumplimiento de <strong>criterios regulatorios y comerciales<\/strong>. \u201c<strong>La carga global del dolor cr\u00f3nico sigue en aumento y un tratamiento efectivo sin opioides sigue siendo esquivo<\/strong>\u201d, destac\u00f3 <strong>Mark Mintun<\/strong>, vicepresidente de investigaci\u00f3n y desarrollo en <strong>neurociencia<\/strong> de Lilly.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El medicamento STC-004 busca abordar la <strong>necesidad urgente de opciones seguras<\/strong> para tratar el <strong>dolor persistente<\/strong>, eliminando riesgos de <strong>adicci\u00f3n<\/strong> y efectos secundarios de los opioides convencionales. Adem\u00e1s, <strong>SiteOne<\/strong> desarrolla otros candidatos para tratar <strong>trastornos sensoriales<\/strong>, como la <strong>tos cr\u00f3nica<\/strong> y el <strong>dolor ocular<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Eli Lilly, reconocida por su enfoque en la investigaci\u00f3n de <strong>diabetes, obesidad y enfermedades del sistema inmune<\/strong>, fortalece su presencia en la <strong>innovaci\u00f3n farmac\u00e9utica<\/strong>, con el prop\u00f3sito de desarrollar <strong>nuevas soluciones terap\u00e9uticas<\/strong> para desaf\u00edos de salud global.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La farmac\u00e9utica Eli Lilly ha anunciado la adquisici\u00f3n de SiteOne Therapeutics, una biotecnol\u00f3gica especializada en el desarrollo de medicamentos no opioides para tratar el dolor cr\u00f3nico y otros trastornos relacionados con la hiperexcitabilidad neuronal. Con esta operaci\u00f3n, Lilly liderar\u00e1 la fase 2 de ensayos cl\u00ednicos del compuesto STC-004, con el objetivo de su futura comercializaci\u00f3n internacional. La transacci\u00f3n permitir\u00e1 a &hellip;<\/p>\n","protected":false},"author":7,"featured_media":5105,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[68],"tags":[1116,1563,1646],"class_list":["post-5104","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-salud","tag-eli-lilly","tag-farmaceutica","tag-siteone-therapeutics"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"La farmac\u00e9utica Eli Lilly ha anunciado la adquisici\u00f3n de SiteOne Therapeutics, una biotecnol\u00f3gica especializada en el desarrollo de medicamentos no opioides para tratar el dolor cr\u00f3nico y otros trastornos relacionados con la hiperexcitabilidad neuronal. Con esta operaci\u00f3n, Lilly liderar\u00e1 la fase 2 de ensayos cl\u00ednicos del compuesto STC-004, con el objetivo de su futura comercializaci\u00f3n\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Poder M\u00e9xico\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.podermexico.mx\/?p=5104\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"es_MX\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Poder M\u00e9xico - Donde los l\u00edderes definen el futuro, exploramos tendencias y desciframos el mundo de la pol\u00edtica y los negocios\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Eli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics - Poder M\u00e9xico\" \/>\n\t\t<meta property=\"og:description\" content=\"La farmac\u00e9utica Eli Lilly ha anunciado la adquisici\u00f3n de SiteOne Therapeutics, una biotecnol\u00f3gica especializada en el desarrollo de medicamentos no opioides para tratar el dolor cr\u00f3nico y otros trastornos relacionados con la hiperexcitabilidad neuronal. Con esta operaci\u00f3n, Lilly liderar\u00e1 la fase 2 de ensayos cl\u00ednicos del compuesto STC-004, con el objetivo de su futura comercializaci\u00f3n\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.podermexico.mx\/?p=5104\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2025-05-29T16:51:04+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-05-29T16:51:06+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Eli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics - Poder M\u00e9xico\" \/>\n\t\t<meta name=\"twitter:description\" content=\"La farmac\u00e9utica Eli Lilly ha anunciado la adquisici\u00f3n de SiteOne Therapeutics, una biotecnol\u00f3gica especializada en el desarrollo de medicamentos no opioides para tratar el dolor cr\u00f3nico y otros trastornos relacionados con la hiperexcitabilidad neuronal. Con esta operaci\u00f3n, Lilly liderar\u00e1 la fase 2 de ensayos cl\u00ednicos del compuesto STC-004, con el objetivo de su futura comercializaci\u00f3n\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=5104#blogposting\",\"name\":\"Eli Lilly consolida la adquisici\\u00f3n de SiteOne Therapeutics - Poder M\\u00e9xico\",\"headline\":\"Eli Lilly consolida la adquisici\\u00f3n de SiteOne Therapeutics\",\"author\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?author=7#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.podermexico.mx\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/66e8525edc545.jpeg\",\"width\":768,\"height\":523},\"datePublished\":\"2025-05-29T16:51:04-06:00\",\"dateModified\":\"2025-05-29T16:51:06-06:00\",\"inLanguage\":\"es-MX\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=5104#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=5104#webpage\"},\"articleSection\":\"Salud, Eli Lilly, Farmac\\u00e9utica, SiteOne Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=5104#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.podermexico.mx\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?cat=68#listItem\",\"name\":\"Salud\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?cat=68#listItem\",\"position\":2,\"name\":\"Salud\",\"item\":\"https:\\\/\\\/www.podermexico.mx\\\/?cat=68\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=5104#listItem\",\"name\":\"Eli Lilly consolida la adquisici\\u00f3n de SiteOne Therapeutics\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=5104#listItem\",\"position\":3,\"name\":\"Eli Lilly consolida la adquisici\\u00f3n de SiteOne Therapeutics\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?cat=68#listItem\",\"name\":\"Salud\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/#organization\",\"name\":\"Poder M\\u00e9xico\",\"description\":\"Donde los l\\u00edderes definen el futuro, exploramos tendencias y desciframos el mundo de la pol\\u00edtica y los negocios\",\"url\":\"https:\\\/\\\/www.podermexico.mx\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?author=7#author\",\"url\":\"https:\\\/\\\/www.podermexico.mx\\\/?author=7\",\"name\":\"Poder M\\u00e9xico\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=5104#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6873d270747c7f511ab0e491b4ef59ff185c68a5912118c90f83cdcd498e434b?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Poder M\\u00e9xico\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=5104#webpage\",\"url\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=5104\",\"name\":\"Eli Lilly consolida la adquisici\\u00f3n de SiteOne Therapeutics - Poder M\\u00e9xico\",\"description\":\"La farmac\\u00e9utica Eli Lilly ha anunciado la adquisici\\u00f3n de SiteOne Therapeutics, una biotecnol\\u00f3gica especializada en el desarrollo de medicamentos no opioides para tratar el dolor cr\\u00f3nico y otros trastornos relacionados con la hiperexcitabilidad neuronal. Con esta operaci\\u00f3n, Lilly liderar\\u00e1 la fase 2 de ensayos cl\\u00ednicos del compuesto STC-004, con el objetivo de su futura comercializaci\\u00f3n\",\"inLanguage\":\"es-MX\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=5104#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?author=7#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?author=7#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.podermexico.mx\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/66e8525edc545.jpeg\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=5104\\\/#mainImage\",\"width\":768,\"height\":523},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=5104#mainImage\"},\"datePublished\":\"2025-05-29T16:51:04-06:00\",\"dateModified\":\"2025-05-29T16:51:06-06:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/#website\",\"url\":\"https:\\\/\\\/www.podermexico.mx\\\/\",\"name\":\"Poder M\\u00e9xico\",\"description\":\"Donde los l\\u00edderes definen el futuro, exploramos tendencias y desciframos el mundo de la pol\\u00edtica y los negocios\",\"inLanguage\":\"es-MX\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Eli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics - Poder M\u00e9xico","description":"La farmac\u00e9utica Eli Lilly ha anunciado la adquisici\u00f3n de SiteOne Therapeutics, una biotecnol\u00f3gica especializada en el desarrollo de medicamentos no opioides para tratar el dolor cr\u00f3nico y otros trastornos relacionados con la hiperexcitabilidad neuronal. Con esta operaci\u00f3n, Lilly liderar\u00e1 la fase 2 de ensayos cl\u00ednicos del compuesto STC-004, con el objetivo de su futura comercializaci\u00f3n","canonical_url":"https:\/\/www.podermexico.mx\/?p=5104","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/www.podermexico.mx\/?p=5104#blogposting","name":"Eli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics - Poder M\u00e9xico","headline":"Eli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics","author":{"@id":"https:\/\/www.podermexico.mx\/?author=7#author"},"publisher":{"@id":"https:\/\/www.podermexico.mx\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.podermexico.mx\/wp-content\/uploads\/2025\/05\/66e8525edc545.jpeg","width":768,"height":523},"datePublished":"2025-05-29T16:51:04-06:00","dateModified":"2025-05-29T16:51:06-06:00","inLanguage":"es-MX","mainEntityOfPage":{"@id":"https:\/\/www.podermexico.mx\/?p=5104#webpage"},"isPartOf":{"@id":"https:\/\/www.podermexico.mx\/?p=5104#webpage"},"articleSection":"Salud, Eli Lilly, Farmac\u00e9utica, SiteOne Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/www.podermexico.mx\/?p=5104#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx#listItem","position":1,"name":"Home","item":"https:\/\/www.podermexico.mx","nextItem":{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx\/?cat=68#listItem","name":"Salud"}},{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx\/?cat=68#listItem","position":2,"name":"Salud","item":"https:\/\/www.podermexico.mx\/?cat=68","nextItem":{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx\/?p=5104#listItem","name":"Eli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx\/?p=5104#listItem","position":3,"name":"Eli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics","previousItem":{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx\/?cat=68#listItem","name":"Salud"}}]},{"@type":"Organization","@id":"https:\/\/www.podermexico.mx\/#organization","name":"Poder M\u00e9xico","description":"Donde los l\u00edderes definen el futuro, exploramos tendencias y desciframos el mundo de la pol\u00edtica y los negocios","url":"https:\/\/www.podermexico.mx\/"},{"@type":"Person","@id":"https:\/\/www.podermexico.mx\/?author=7#author","url":"https:\/\/www.podermexico.mx\/?author=7","name":"Poder M\u00e9xico","image":{"@type":"ImageObject","@id":"https:\/\/www.podermexico.mx\/?p=5104#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/6873d270747c7f511ab0e491b4ef59ff185c68a5912118c90f83cdcd498e434b?s=96&d=mm&r=g","width":96,"height":96,"caption":"Poder M\u00e9xico"}},{"@type":"WebPage","@id":"https:\/\/www.podermexico.mx\/?p=5104#webpage","url":"https:\/\/www.podermexico.mx\/?p=5104","name":"Eli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics - Poder M\u00e9xico","description":"La farmac\u00e9utica Eli Lilly ha anunciado la adquisici\u00f3n de SiteOne Therapeutics, una biotecnol\u00f3gica especializada en el desarrollo de medicamentos no opioides para tratar el dolor cr\u00f3nico y otros trastornos relacionados con la hiperexcitabilidad neuronal. Con esta operaci\u00f3n, Lilly liderar\u00e1 la fase 2 de ensayos cl\u00ednicos del compuesto STC-004, con el objetivo de su futura comercializaci\u00f3n","inLanguage":"es-MX","isPartOf":{"@id":"https:\/\/www.podermexico.mx\/#website"},"breadcrumb":{"@id":"https:\/\/www.podermexico.mx\/?p=5104#breadcrumblist"},"author":{"@id":"https:\/\/www.podermexico.mx\/?author=7#author"},"creator":{"@id":"https:\/\/www.podermexico.mx\/?author=7#author"},"image":{"@type":"ImageObject","url":"https:\/\/www.podermexico.mx\/wp-content\/uploads\/2025\/05\/66e8525edc545.jpeg","@id":"https:\/\/www.podermexico.mx\/?p=5104\/#mainImage","width":768,"height":523},"primaryImageOfPage":{"@id":"https:\/\/www.podermexico.mx\/?p=5104#mainImage"},"datePublished":"2025-05-29T16:51:04-06:00","dateModified":"2025-05-29T16:51:06-06:00"},{"@type":"WebSite","@id":"https:\/\/www.podermexico.mx\/#website","url":"https:\/\/www.podermexico.mx\/","name":"Poder M\u00e9xico","description":"Donde los l\u00edderes definen el futuro, exploramos tendencias y desciframos el mundo de la pol\u00edtica y los negocios","inLanguage":"es-MX","publisher":{"@id":"https:\/\/www.podermexico.mx\/#organization"}}]},"og:locale":"es_MX","og:site_name":"Poder M\u00e9xico - Donde los l\u00edderes definen el futuro, exploramos tendencias y desciframos el mundo de la pol\u00edtica y los negocios","og:type":"article","og:title":"Eli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics - Poder M\u00e9xico","og:description":"La farmac\u00e9utica Eli Lilly ha anunciado la adquisici\u00f3n de SiteOne Therapeutics, una biotecnol\u00f3gica especializada en el desarrollo de medicamentos no opioides para tratar el dolor cr\u00f3nico y otros trastornos relacionados con la hiperexcitabilidad neuronal. Con esta operaci\u00f3n, Lilly liderar\u00e1 la fase 2 de ensayos cl\u00ednicos del compuesto STC-004, con el objetivo de su futura comercializaci\u00f3n","og:url":"https:\/\/www.podermexico.mx\/?p=5104","article:published_time":"2025-05-29T16:51:04+00:00","article:modified_time":"2025-05-29T16:51:06+00:00","twitter:card":"summary_large_image","twitter:title":"Eli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics - Poder M\u00e9xico","twitter:description":"La farmac\u00e9utica Eli Lilly ha anunciado la adquisici\u00f3n de SiteOne Therapeutics, una biotecnol\u00f3gica especializada en el desarrollo de medicamentos no opioides para tratar el dolor cr\u00f3nico y otros trastornos relacionados con la hiperexcitabilidad neuronal. Con esta operaci\u00f3n, Lilly liderar\u00e1 la fase 2 de ensayos cl\u00ednicos del compuesto STC-004, con el objetivo de su futura comercializaci\u00f3n"},"aioseo_meta_data":{"post_id":"5104","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2025-05-29 16:51:06","updated":"2025-07-13 06:35:07","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.podermexico.mx\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.podermexico.mx\/?cat=68\" title=\"Salud\">Salud<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tEli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.podermexico.mx"},{"label":"Salud","link":"https:\/\/www.podermexico.mx\/?cat=68"},{"label":"Eli Lilly consolida la adquisici\u00f3n de SiteOne Therapeutics","link":"https:\/\/www.podermexico.mx\/?p=5104"}],"_links":{"self":[{"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/posts\/5104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5104"}],"version-history":[{"count":1,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/posts\/5104\/revisions"}],"predecessor-version":[{"id":5106,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/posts\/5104\/revisions\/5106"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/media\/5105"}],"wp:attachment":[{"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}